Study Shows How Paxlovid Resistance Emerges in Persistent Infections
Paxlovid is still a highly effective treatment for most people infected with SARS-CoV-2 and the drug prevents many hospitalizations and deaths from COVID.
But for millions of immunocompromised people whose infections may persist for months, the antiviral drug can lose its effectiveness as the virus mutates. Although patients may initially experience a decrease in viral load, as these mutations arise, the virus can return unimpeded by the drug, bringing the risk of disease and even death.
“This type of approach helped to improve HIV drugs, and we think it’s a good way to improve antivirals against SARS-CoV-2,” says Sho Iketani, PhD, assistant professor of medical sciences at Columbia University’s Vagelos College of Physicians and Surgeons and Aaron Diamond AIDS Research Center, who co-led the research with David D. Ho, MD, the Clyde '56 and Helen Wu Professor of Medicine, professor of microbiology & immunology, and director of the Aaron Diamond AIDS Research Center, and Haitao Yang, PhD, of ShanghaiTech University.
“Right now, patients only have three antiviral drug options, nirmatrelvir (the active ingredient in Paxlovid), remdesivir, and molnupiravir. More choice is always better.”
Escape mutations in SARS-CoV-2
In the study, Iketani and colleagues looked at how mutations allow the virus to evade nirmatrelvir. Images of the drug when bound to its viral target, Mpro, revealed that mutations in the binding pocket have the greatest effect and prevent the drug from binding.
The same mutations also allowed the coronavirus to escape another Mpro inhibitor, Japan’s ensitrelvir, but to a lesser degree, providing clues to how Mpro inhibitors could be improved.
Paxlovid-resistant viruses with these mutations have been found in some immunocompromised patients and others with persistent infections.
“The good news is that it seems that the virus suffers a pretty big fitness penalty when it develops resistance, so I don’t think we’ll see resistant variants spread widely if it must balance this loss,” Iketani says.
Paxlovid-resistant variants of SARS-CoV-2 are also unlikely to develop outside of the immunocompromised population. “Because otherwise healthy individuals taking Paxlovid will rapidly clear the virus, the opportunity for the virus to mutate to evade the drug in the general population is low,” Iketani says.
The paper is titled, “Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.”
All authors: Yinkai Duan (ShanghaiTech University), Hao Zhou (ShanghaiTech), Xiang Liu (Nankai University, Tianjin, China), Sho Iketani (Columbia), Mengmeng Lin (ShanghaiTech and Chongqing Medical University), Xiaoyu Zhang (ShanghaiTech), Qucheng Bian (ShanghaiTech), Haofeng Wang (ShanghaiTech), Haoran Sun (ShanghaiTech), Seo Jung Hong (Columbia), Bruce Culbertson (Columbia), Hiroshi Mohri (Columbia), Maria I. Luck (Columbia), Yan Zhu (ShanghaiTech), Xiaoce Liu (ShanghaiTech), Yuchi Lu (ShanghaiTech), Xiuna Yang (ShanghaiTech), Kailin Yang (Cleveland Clinic), Yosef Sabo (Columbia), Alejandro Chavez (Columbia), Stephen P. Goff (Columbia), Zihe Rao (ShanghaiTech) , David D. Ho (Columbia), and Haitao Yang (ShanghaiTech).
This work was supported by grants from Guangzhou Laboratory (SRPG22-003 and SRPG22-011); Science and Technology Commission of Shanghai Municipality (YDZX20213100001556 and 20XD1422900); National Natural Science Foundation of China (92169109); Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine of ShanghaiTech University, and a Career Award for Medical Scientists from the Burroughs Wellcome Fund.
Sho Iketani, Alejandro Chavez, and David Ho are inventors on patent applications related to the development of inhibitors against the SARS-CoV-2 3CL protease. David Ho is a co-founder of TaiMed Biologics and RenBio, consultant to WuXi Biologics and Brii Biosciences, and board director for Vicarious Surgical.